Literature DB >> 20865660

Expression of mitotic kinases phospho-aurora A and aurora B correlates with clinical and pathological parameters in bladder neoplasms.

Pantaleo Bufo1, Francesca Sanguedolce, Simona Tortorella, Luigi Cormio, Giuseppe Carrieri, Giuseppe Pannone.   

Abstract

Aurora A and Aurora B are serine-threonine kinase proteins which have both been implicated in human carcinogenesis through development of aneuploidy and chromosomal instability. The aim of the study is to assess the correlation of both markers with clinical and pathological parameters in patients with bladder cancer of different grade and stage. A bladder cancer cell line was assessed for Aurora A and Aurora B expression by Western blotting. Furthermore, 85 consecutive cases of bladder neoplasms obtained by transurethral resection were quantitatively and qualitatively analysed by immunohistochemistry for Phospho-Aurora A and Aurora B expression. All cases were stratified in 4 groups according to intracellular localization (nuclear, cytoplasmic) of both markers. The association between each group and clinical and pathological parameters was assessed by statistical analysis. Higher expression of cytoplasmic Phospho-Aurora A correlated significantly with poor histological differentiation (G3 vs. G1) and advanced stage (p<0.05); there was also high significant correlation between nuclear Aurora B and both grading (both G3 and G2 vs. G1) and mitotic index (p<0.05). No statistically significant association was found between protein levels detected in tumour and sex or age (p>0.05). To our knowledge, the present study is the first to highlight the existence of a statistical association between such markers and traditional prognostic factors in bladder cancer. These findings indicate that Aurora A and B could be involved in the tumorigenesis of bladder cancer, thus providing a basis for a target therapy approach by using specific anti-mitotic agents.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20865660     DOI: 10.14670/HH-25.1371

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  12 in total

Review 1.  Muscle-invasive urothelial bladder cancer: an update on systemic therapy.

Authors:  Hayley Knollman; J Luke Godwin; Rishi Jain; Yu-Ning Wong; Elizabeth R Plimack; Daniel M Geynisman
Journal:  Ther Adv Urol       Date:  2015-12

2.  Aurora A Kinase as a diagnostic urinary marker for urothelial bladder cancer.

Authors:  Michela de Martino; Shahrokh F Shariat; Sebastian L Hofbauer; Ilaria Lucca; Christopher Taus; Helene G Wiener; Andrea Haitel; Martin Susani; Tobias Klatte
Journal:  World J Urol       Date:  2014-02-23       Impact factor: 4.226

3.  [Use of marker systems in the treatment of bladder cancer].

Authors:  M Burger; F Vom Dorp
Journal:  Urologe A       Date:  2011-03       Impact factor: 0.639

4.  Aneuploidy, oncogene amplification and epithelial to mesenchymal transition define spontaneous transformation of murine epithelial cells.

Authors:  Hesed M Padilla-Nash; Nicole E McNeil; Ming Yi; Quang-Tri Nguyen; Yue Hu; Danny Wangsa; David L Mack; Amanda B Hummon; Chanelle Case; Eric Cardin; Robert Stephens; Michael J Difilippantonio; Thomas Ried
Journal:  Carcinogenesis       Date:  2013-04-25       Impact factor: 4.944

5.  The investigational Aurora kinase A inhibitor MLN8237 induces defects in cell viability and cell-cycle progression in malignant bladder cancer cells in vitro and in vivo.

Authors:  Ning Zhou; Kamini Singh; Maria C Mir; Yvonne Parker; Daniel Lindner; Robert Dreicer; Jeffrey A Ecsedy; Zhongfa Zhang; Bin T Teh; Alexandru Almasan; Donna E Hansel
Journal:  Clin Cancer Res       Date:  2013-02-12       Impact factor: 12.531

6.  Molecular mechanism and therapeutic implications of selinexor (KPT-330) in liposarcoma.

Authors:  Manoj Garg; Deepika Kanojia; Anand Mayakonda; Jonathan W Said; Ngan B Doan; Wenwen Chien; Trivadi S Ganesan; Linda Shyue Huey Chuang; Nachiyappan Venkatachalam; Erkan Baloglu; Sharon Shacham; Michael Kauffman; H Phillip Koeffler
Journal:  Oncotarget       Date:  2017-01-31

7.  Identification of key candidate genes and biological pathways in bladder cancer.

Authors:  Xin Gao; Yinyi Chen; Mei Chen; Shunlan Wang; Xiaohong Wen; Shufang Zhang
Journal:  PeerJ       Date:  2018-12-04       Impact factor: 2.984

8.  Identification of pVHL as a novel substrate for Aurora-A in clear cell renal cell carcinoma (ccRCC).

Authors:  Benedicte Martin; Franck Chesnel; Jean-Guy Delcros; Florence Jouan; Anne Couturier; Frederic Dugay; Xavier Le Goff; Jean-Jacques Patard; Patricia Fergelot; Cecile Vigneau; Nathalie Rioux-Leclerq; Yannick Arlot-Bonnemains
Journal:  PLoS One       Date:  2013-06-13       Impact factor: 3.240

Review 9.  Asymptomatic solitary bladder plasmocytoma: A case report and literature review.

Authors:  Luigi Cormio; Vito Mancini; Beppe Calò; Oscar Selvaggio; Teobaldo Mazzilli; Francesca Sanguedolce; Giuseppe Carrieri
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

Review 10.  Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data.

Authors:  Matteo Giulietti; Giulia Occhipinti; Alessandra Righetti; Massimo Bracci; Alessandro Conti; Annamaria Ruzzo; Elisabetta Cerigioni; Tiziana Cacciamani; Giovanni Principato; Francesco Piva
Journal:  Front Oncol       Date:  2018-10-12       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.